Mobile Origins, a TTP Firm, targeted on enabling scalable, cost-effective, and environment friendly manufacture of cell and gene therapies (CGTs), immediately introduced the acquisition of the ACTIA (Autologous Cell Remedy Industrial Automation) Platform IP, developed by Geoff Hodge while CEO of SOTIO Biotech US. The ACTIA Platform enhances Mobile Origins’ present method and can speed up and broaden R&D efforts to additional develop the Firm’s robotic resolution for automated cell remedy manufacturing, Constellation™.
Launched in Could 2023, Constellation combines superior automation robotics with aseptic fluid-handling applied sciences in a extremely versatile and scalable system. Uniquely, the platform bodily and digitally integrates with a variety of present bioprocessing tools, enabling customers to undertake its use with out requiring important adjustments to both the workflow or tools, assuaging the dangers and time that include course of redevelopment.
The ACTIA Platform is concentrated on the wants of autologous cell remedy manufacturing and permits for massively multiplex and distributed industrial automation. With this expertise, customers can selectively improve capability to focus on course of bottlenecks, sometimes the enlargement step, alongside random entry to any course of step or affected person dose. Finally, the platform allows really industrialized, versatile and extremely environment friendly manufacture.
The acquisition of the ACTIA IP platform continues the continued drive by Mobile Origins to deal with the challenges of producing cell therapies at scale. Complementing the Firm’s current partnership with the Cell and Gene Remedy Catapult to develop distinctive methods for seamless integration of bioprocessing tools, the ACTIA platform will allow cell remedy builders entry to best-in-class unit operations throughout the Constellation platform. Taken collectively, these key developments will assist prospects obtain quicker routes to scalable manufacture of cell therapies while concurrently decreasing threat.
The acquisition of the ACTIA Platform IP reveals Mobile Origins continued dedication to creating essentially the most environment friendly, price efficient and scalable resolution to cell remedy manufacturing. Mixed with ongoing R&D, this enlargement of our expertise and IP portfolio underpins our dedication to develop Constellation to resolve the problem of inexpensive, large-scale manufacturing of cell therapies that meets the wants of our prospects and ensures we will provide the correct resolution for long-term success.”
Dr Edwin Stone, CEO at Mobile Origins
Geoffrey Hodge, former CEO of SOTIO Biotech US and Scientific Advisor, Mobile Origins, commented: “The method of stringing collectively sequential unit ops, as we did to fabricate recombinant proteins, doesn’t meet the distinctive wants of autologous cell remedy. Constellation has already demonstrated its capabilities to rework manufacturing of cell therapies, providing an simply accessible path to cost- and space-efficient, large-scale manufacturing. ACTIA additional augments Constellation, and the ambition to revolutionize cell remedy manufacturing and ship life-saving therapies to extra sufferers than ever earlier than.”
